Editas Medicine vs Emendo Biotherapeutics
Editas Medicine vs Emendo Biotherapeutics, compared side by side on 20 data points: what each one does, how big it is, what it has raised, the tech running each site, and what users report. We score both out of 100 on traction, team and visibility: Editas Medicine is on 42/100 and Emendo Biotherapeutics on 59/100.
Where each one leads
Editas Medicine
- domain rating: 61/100 against 20/100
- headcount: 185 against 41
- funding raised: $210M against $61.0M
- LinkedIn following: 52,616 against 5,333
Emendo Biotherapeutics
- our overall score: 59/100 against 42/100
At a glance
| Measure | Editas Medicine | Emendo Biotherapeutics |
|---|---|---|
| What it is | A clinical-stage biotechnology company developing transformative genome editing medicines for serious diseases. | Developing genetic medicines and cell therapies for severe diseases using proprietary CRISPR OMNI technology. |
| Category | Biotech, MedTech, Genomics, Drug Discovery | Healthcare, Genome Editing, CRISPR, Biotech |
| Sells toBusiness model | B2B | B2B |
| Offering | Platform | Platform |
| Founded | 2013 | 2015 |
| Headquarters | Cambridge, United States | Tel Aviv, Israel |
| Status | Active | Active |
Size, funding and growth
| Measure | Editas Medicine | Emendo Biotherapeutics |
|---|---|---|
| Employees | 185 | 41 |
| Headcount growthLast 12 months | Not published | -16.1% |
| Total funding | $210M | $61.0M |
| Latest round | Series B | Series B |
| LinkedIn followers | 52,616 | 5,333 |
StartupHub scores
Our own 0-100 ratings. They measure company strength and site quality, not which product suits you.
| Measure | Editas Medicine | Emendo Biotherapeutics |
|---|---|---|
| StartupHub scoreOur 0-100 rating | 42/100 | 59/100 |
| Traction | 60/100 | 55/100 |
| Team | Not published | 40/100 |
| Search visibility | 27/100 | 44/100 |
| Quality | 45/100 | 68/100 |
| Agent readinessHow well an AI agent can read and act on the site | F (39/100) | D (40/100) |
| Domain ratingLink authority, 0-100 | 61/100 | 20/100 |
Technology
Detected on each public site, so it reflects the marketing stack as well as the product.
| Measure | Editas Medicine | Emendo Biotherapeutics |
|---|---|---|
| Hosting | Not detected | Google Cloud |
| CDN | Cloudflare | Not detected |
| CMS | WordPress | WordPress |
| Frameworks | Jquery, Tailwind CSS, Bootstrap | Bootstrap |
| Analytics | Google Tag Manager | Google Tag Manager |
Editas Medicine vs Emendo Biotherapeutics: common questions
Which is better, Editas Medicine or Emendo Biotherapeutics?
On our 0-100 score Emendo Biotherapeutics rates higher (59/100 against 42/100). The score weights traction, team, visibility and profile completeness, so it reflects company strength rather than which product suits you. We compare the two on 20 data points above: read the rows that match what you are buying for.
How do Editas Medicine and Emendo Biotherapeutics compare on the numbers?
Editas Medicine leads on domain rating (61/100 against 20/100), headcount (185 against 41), funding raised ($210M against $61.0M), LinkedIn following (52,616 against 5,333). Emendo Biotherapeutics leads on our overall score (59/100 against 42/100).
Read the full Editas Medicine review and pricing or the Emendo Biotherapeutics review and pricing. You can also browse other Editas Medicine alternatives we track.